Compare · DXCM vs LUCD
DXCM vs LUCD
Side-by-side comparison of DexCom Inc. (DXCM) and Lucid Diagnostics Inc. (LUCD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and LUCD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 390.0x LUCD ($75.9M).
- DXCM has been more active in the news (10 items in the past 4 weeks vs 7 for LUCD).
- DXCM has more recent analyst coverage (25 ratings vs 6 for LUCD).
- Company
- DexCom Inc.
- Lucid Diagnostics Inc.
- Price
- -
- -
- Market cap
- $29.58B
- $75.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 10
- 7
- Recent ratings
- 25
- 6
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Latest DXCM
- Dexcom Marks Athenry Opening With Celebration of Commercial Production Milestone
- EVP Chief Legal Compliance Off Michael Jon Brown sold $141,882 worth of shares (1,700 units at $83.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 95,034 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 96,734 units (SEC Form 4) to cover withholding tax
- EVP, COO & CFO Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.99% to 145,377 units (SEC Form 4) (for tax liability)
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 119,462 units (SEC Form 4) to satisfy withholding obligation
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 417,457 units (SEC Form 4) to satisfy withholding tax
- Dexcom Announces Upcoming Conference Presentation
- SEC Form SCHEDULE 13G filed by DexCom Inc.
- Director Ashley Euan A. gifted 2,389 shares (SEC Form 4)
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
Latest LUCD
- PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
- SEC Form 10-Q filed by Lucid Diagnostics Inc.
- Lucid Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
- Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
- Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study
- PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
- Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
- Oil Above $100 Puts Penny Stocks in Focus